Insulin Aspart

China [CN]

Gestational diabetes mellitus (gestationaldiabetesmellitus) can lead to a variety of maternal and infant hazards such as fetal distress, hydramnios, severe cases, even cause miscarriage or stillbirth. With the improvement of living standards, poor dietary structure and living habits have led to an increasing incidence of gestational diabetes year by year. Literature reports that the incidence of gestational diabetes is 1% to 5%, and it has become one of the main diseases affecting the health of pregnant women and their fetuses. For the treatment of gestational diabetes, non-pharmaceutical therapies such as dietary control are the first choice. Drug therapy often involves insulin and insulin analogues, but only aspartate insulin, one insulin analogue, has been approved by the National Medical Products Administration. Insulin aspartate is a new type of insulin analogue, which is a fast-acting insulin analogue synthesized by recombinant DNA technology using brewed yeast precursor (the proline at position 28 of the human insulin B chain is replaced by aspartate residues). This product has exactly the same structure as natural human insulin in other aspects. It binds to insulin receptors on muscle and fat cells to promote glucose uptake, while simultaneously inhibiting the release of glucose from the liver, thereby playing a role in lowering blood sugar. It is clinically used for type 1 and type 2 diabetes with poor disease control. The dosage of this product is individualized. Under normal circumstances, it should be used in combination with medium-acting or long-acting insulin. Subcutaneous administration, at least once a day. The use of this product may cause hypoglycemia, local and systemic allergic reactions. If the injection sites are not rotated in the same area, fatty dystrophy may occur. This product is contraindicated for people with hypoglycemia and those allergic to it. Insulin aspartate takes effect rapidly after subcutaneous injection, reaching its peak efficacy 30 to 60 minutes after injection, which precisely matches the peak of postprandial blood glucose in humans. The large doses taken before each meal fully act to lower the postprandial blood glucose of the current meal. Under the same conditions, the proportion of the pre-meal dose to the total daily dose in insulin pump treatment is lower.